The World Health Organization (WHO) has released its first-ever guidelines for diagnosing and managing type 1 diabetes in adults, seeking to address persistent barriers to life-saving treatment, particularly in countries with limited healthcare resources.
Announced ahead of World Diabetes Day 2026, the guidelines provide evidence-based recommendations to help countries strengthen diabetes care across different healthcare environments, including emergency and humanitarian settings where access to essential medical services may be disrupted.
The move comes more than a century after the discovery of insulin, yet millions of people living with type 1 diabetes continue to face challenges accessing affordable insulin and the regular monitoring required to manage the condition.
Type 1 diabetes is a lifelong condition in which the body produces insufficient insulin, a hormone essential for regulating blood glucose. People living with the condition therefore depend on daily insulin treatment to survive.
WHO estimates that approximately 9.5 million people worldwide were living with type 1 diabetes in 2025, with another 500,000 receiving a diagnosis during the year. Although the condition is commonly associated with children, the organisation says it is increasingly affecting adults, highlighting the need for healthcare systems to improve diagnosis and long-term management across age groups.
Dr Søren Brostrøm, WHO Director of Noncommunicable Diseases and Mental Health, said the guidelines respond to continuing inequalities in access to affordable, quality insulin despite the treatment having been available for more than 100 years.
He noted that the recommendations would support countries in delivering effective diabetes care, including in settings where financial and healthcare resources are constrained.
Under the new guidance, WHO recommends that adults with type 1 diabetes receive multiple daily insulin injections, with treatment adjusted according to their blood glucose levels.
The organisation identifies human insulin as an effective and appropriate treatment option, while recognising that other insulin formulations may be used depending on individual needs and clinical circumstances.
The guidelines also emphasise the importance of consistent blood glucose monitoring to support treatment decisions and reduce the risk of complications.
Monitoring can be conducted through regular clinical blood tests that measure average blood glucose over several months, as well as home-based methods such as finger-prick testing and continuous glucose monitoring devices. These devices use small sensors attached to the skin to track glucose levels.
For healthcare settings where blood glucose testing is unavailable, WHO says urine glucose testing can be considered as an alternative.
The recommendations are also aligned with WHO’s 2030 diabetes targets, which seek to ensure that everyone living with type 1 diabetes has access to affordable insulin treatment and blood glucose self-monitoring.
To support implementation, WHO says it will work with countries by providing practical tools and guidance to monitor progress and translate the recommendations into improved healthcare services.
The organisation is further urging governments to involve people living with type 1 diabetes in the design, implementation and evaluation of national diabetes programmes, recognising the importance of patient experiences in shaping effective health interventions.
The guidelines come against the backdrop of a growing global diabetes burden. WHO estimates that 830 million people were living with diabetes worldwide in 2022, with the majority affected by type 2 diabetes.
The global burden has more than quadrupled since 1990, while more than 40 per cent of people living with diabetes remain unaware of their condition, leaving many without timely diagnosis and appropriate care.
Unmanaged diabetes can result in severe complications, including cardiovascular disease, stroke, kidney failure, blindness and lower-limb amputation.
This year’s World Diabetes Day is being observed under the theme, “Early action on diabetes,” highlighting the importance of timely diagnosis, treatment and sustained access to healthcare.
By establishing its first dedicated guidelines for adult type 1 diabetes management, WHO aims to help countries address treatment inequalities and strengthen access to essential care, particularly for populations living in resource-constrained and crisis-affected settings.


